Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2021-08-18
Target enrollment:
Participant gender:
Summary
The aim of this study is to perform a comparison of the efficacy and safety of empagliflozin
and vildagliptin in patients with Type 2 Diabetes Mellitus
open labelled, multi-centric, parallel, randomized control trial
In Type 2 Diabetes patients, impact of empagliflozin (10 mg once or twice daily) versus
vildagliptin (50 mg once or twice daily) assessed for Efficacy & safety parameters to be
measured at both the baseline and 24-week visits.